) The goal of the proposed studies is to design a multi-epitope-based vaccine for the treatment and prophylaxis of HCV-infected patients. Such a vaccine will be designed to induce antigen-specific CTL and HTL responses and provide broad population coverage. Immunogenic CTL epitopes from 3 major HLA supertypes will be identified through in vivo studies in HLA transgenic mice, and in vitro studies with PBMCs obtained from HCV-infected patients. An appropriate system for delivery of multiple epitopes will also be identified. Specifically, the ability of cDNA minigenes to deliver multiple epitopes will be compared to lipopeptide cocktails and whole gene cDNA with regard to breadth and magnitude of the response.

Proposed Commercial Applications

NOT AVAILABLE

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44AI038620-02
Application #
2644588
Study Section
Special Emphasis Panel (ZRG2-SSS-4 (02))
Project Start
1995-08-01
Project End
2000-09-29
Budget Start
1998-09-30
Budget End
1999-09-29
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Cytel Corporation
Department
Type
DUNS #
City
San Diego
State
CA
Country
United States
Zip Code
92121